Overview

A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering

Status:
Suspended

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this research study is to find out the potential benefits and safety of asenapine (Saphris®) in adults who suffer from the developmental form of stuttering. It is hypothesized that individuals who are randomly assigned to asenapine will have an improvement in speech as compared to a placebo.

Phase:

Phase 3

Details

Lead Sponsor:

University of California, Irvine

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Asenapine